PHE Authors Awarded 2017 JMCP Award for Excellence
Congratulations to PHE authors Joanna MacEwan, Jason Shafrin, and Darius Lakdawalla who along with co-authors Felicia Forma, Ainslie Hatch and Jean-Pierre Lindenmayer have been awarded the 2017 JMCP Award for Excellence.
The JMCP Award for Excellence is annual award recognizing a single article that represents the best scholarly work in managed care pharmacy. The paper, “Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia,” brings a cutting-edge statistical technique to the analysis of adherence to serious mental illness medicines.
The winner of the Award for Excellence is determined by a 7-member panel of judges convened each year comprised of three members of the JMCP Editorial Advisory Board, and four JMCP Peer Reviewers who have contributed high-quality reviews. The nominated articles are evaluated by the Judges Panel according to the following measures and weights:
- Impact on the profession or knowledge (30%)
- Relevance to managed care pharmacy today (30%)
- Scientific merit and sound methodology (20%)
- Clarity of purpose and hypothesis (10%)
- Writing quality and readibility (10%)
The JMCP Award for Excellence is presented annually at the AMCP Annual Meeting.
To read the winning article, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.